Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Liberty Wealth Management LLC

Liberty Wealth Management LLC decreased its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 27.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,978 shares of the company’s stock after selling 3,405 shares during the period. Liberty Wealth Management LLC’s holdings in Hims & Hers Health were worth $217,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. SPX Gestao de Recursos Ltda acquired a new position in Hims & Hers Health during the fourth quarter worth about $1,814,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Hims & Hers Health by 16.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,450 shares of the company’s stock valued at $785,000 after purchasing an additional 4,620 shares during the period. Amundi grew its holdings in Hims & Hers Health by 49.1% in the fourth quarter. Amundi now owns 12,741 shares of the company’s stock valued at $328,000 after purchasing an additional 4,197 shares during the period. PNC Financial Services Group Inc. grew its holdings in Hims & Hers Health by 51.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 17,225 shares of the company’s stock valued at $417,000 after purchasing an additional 5,885 shares during the period. Finally, Jackson Creek Investment Advisors LLC acquired a new position in Hims & Hers Health during the fourth quarter valued at approximately $1,284,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Trading Down 2.0 %

Shares of NYSE HIMS opened at $34.00 on Thursday. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98. The company has a market capitalization of $7.55 billion, a price-to-earnings ratio of 77.27 and a beta of 1.37. The firm has a 50-day moving average of $38.23 and a two-hundred day moving average of $27.90.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. As a group, research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In other news, insider Soleil Boughton sold 268,932 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the completion of the sale, the insider now owns 169,803 shares in the company, valued at approximately $4,712,033.25. This represents a 61.30 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Michael Chi sold 17,303 shares of Hims & Hers Health stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $48.14, for a total transaction of $832,966.42. Following the completion of the transaction, the insider now directly owns 193,601 shares in the company, valued at approximately $9,319,952.14. This represents a 8.20 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 969,191 shares of company stock valued at $34,005,375. Insiders own 17.71% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Morgan Stanley cut shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. BTIG Research started coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target on the stock. Needham & Company LLC boosted their target price on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th. Canaccord Genuity Group boosted their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Finally, TD Cowen restated a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $37.23.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.